NCT06419322Completed
Acceptability, Feasibility, Safety and Efficacy of a Optimized Rehabilitation Program for Treated Patients With Spinal Muscular Atrophy (SMA).
A Monocentric, Prospective and Longitudinal Study Investigating the Acceptability, Feasibility, Safety and Efficacy of an Optimized Rehabilitation Program for Treated Patients With SMA Compared to the Current Rehabilitation Program in United Kingdom: ACE SMA.
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
The goal of this study is to investigate the acceptability, feasibility, safety and efficacy of an optimized rehabilitation program for treated patients with spinal muscular atrophy (SMA) compared to the current rehabilitation program in the United Kingdom. The aim is to provide patients with more hands on physiotherapy and access to rehabilitation devices at home to support parents currently providing rehabilitation on their own.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 14 (actual)
- First submitted
- 2 May 2024
- Start date
- 1 Jun 2024
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- University of Oxford
- Diseases
- Spinal muscular atrophy
- NCT number
- NCT06419322
What you commit to
- Study type: Interventional
- Participants enrolled: 14
- From 1 Jun 2024 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently enrolled in a treatment study; or treatment with an experimental therapy
- Any surgical and/or medical intervention, according to the investigator, 3 months before baseline and/or during the study participation.
- Carer (considered as participant) Eligibility Criteria:
Other illness
- Any acute or chronic condition which, as assessed by the investigator, significantly interferes with the rehabilitation of the patient
Other
- The participant may not enter the trial if ANY of the following apply:
- Need of diurnal and/or invasive ventilation, naps excluded
- No exclusion criteria.
Who the study is looking for
- Genetically confirmed SMA considered as a non-sitter, sitter or walker
- Post-symptomatically treated and on stable dose for 12 months with any disease-modifying market-approved drug
- Patients from 1-10 years of age at baseline
- Parent(s)/legal guardian(s) of patients less than 16 years of age must provide written informed consent prior to the patient's participation in the study
- Willing and able to comply with all protocol requirements and procedures.
- Willing and able to comply with all protocol requirements and procedures
- Carer's child has been included in study.
Criteria the registry did not label
- Patient participant Eligibility Criteria:
Age in the registry: 1 year to 10 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oxford Brookes University Coordinator of this site? Confirm its status | Oxford | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.